Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Inflammatory molecule reduction with hydroxyurea therapy in children with sickle cell anemia
source: Haematologica
year: 2018
authors: Penkert RR, Hurwitz JL, Thomas P, Rosch J, Dowdy J, Sun Y, Tang L, Hankins JS
summary/abstract:Children with sickle cell anemia (SCA) suffer from a chronic state of inflammation due to repeated tissue insult from sickling red blood cells. The clinical consequences are severe and involve aberration of inflammatory systems, with associated increased activation of multiple cell types, including platelets, neutrophils, and eosinophils.1,2 The literature has described a reduction of inflammatory molecules by hydroxyurea, but results have been limited, and at times contradictory.3–8 In fact, some researchers reported that patients receiving hydroxyurea exhibited increased levels of interleukin (IL)-6 compared to untreated patients,9 while others reported a decrease in IL-6 levels in patients after initiating hydroxyurea therapy,10 albeit neither finding reached statistical significance (perhaps due to small study numbers). Herein, we address discrepancies by reporting a comprehensive study in which 214 patients with SCA were assessed, 122 of whom were sampled longitudinally.
We compared patients on hydroxyurea (both initial and sustained therapy) with patients on chronic blood transfusions or no treatment. In grouped analyses, hydroxyurea proved to be the better treatment for reduction of inflammatory molecules. During the 2-year observation period, children continued to benefit from hydroxyurea treatment, although they did not achieve profiles similar to those of healthy controls. Patients receiving continuous chronic blood transfusion therapy or no treatment showed fewer reductions in factor levels compared to hydroxyurea. In total, our data illustrated the long-term, but incomplete benefit of hydroxyurea for reduction of inflammatory molecules in patients with SCA.
organization: University of Tennessee Health Science Center, USADOI: 10.3324/haematol.2017.177360
read more full text
Related Content
-
A Pill a Day for Sickle Cellhttps://www.youtube.com/watch?v=8YkBNxZ4...
-
Young Sickle Cell Patients Who Don’t Take Medication Have Lower Quality of LifeAdolescents and young adults with sickle...
-
Intentional and Unintentional Nonadherence to Hydroxyurea Among People With Sickle Cell Disease: A Qualitative StudyHydroxyurea is an efficacious treatment ...
-
A Clinically Meaningful Fetal Hemoglobin Threshold for Children With Sickle Cell Anemia During Hydroxyurea TherapyHydroxyurea has proven clinical benefits...
-
Study challenges view that sickle cell trait increases mortality riskSurprising findings from a study of heal...
-
The ‘Voice of Lagos’ is silent: Entertainer Tosyn Bucknor dies at 37Nigerians are paying tribute t...
-
Screening for sickle cell and beta thalassaemiaSickle cell and beta thalassaemi...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.